New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
13:45 EDTFB, GOOG, AAPLFacebook to try to woo developers to use app store, Business Insider says
On April 30, Facebook (FB) will tell developers at a conference that its app store is a much more effective way to market apps than Apple's (AAPL) and Google's (GOOG) app store, according to Business Insider. Facebook has over 1B users, and they can be broken down by sex, age, location, interest, and many other variables, according to Business Insider, which notes that the global app market is growing rapidly. Reference Link
News For FB;GOOG;AAPL From The Last 14 Days
Check below for free stories on FB;GOOG;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
July 15, 2014
16:00 EDTAAPL, GOOG, FBOptions Update; July 15, 2014
iPath S&P 500 VIX Short-Term Futures up 53c to 28.02. Option volume leaders: AAPL FB GOOG AMZN ABX DIS NFLX TWTR TSLA according to Track Data.
12:55 EDTAAPLEarnings Preview: Intel up over 12% since pre-announcement
Intel (INTC) is expected to report second quarter earnings after the close on Tuesday, July 15, with a conference call scheduled for 5:00 pm ET. Intel is a global semiconductor manufacturer and a member of the Dow Jones Industrial Average. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.69B. The consensus range is 45c-55c for EPS on revenue of $13.0B-$14.0B, according to First Call. Along with its first quarter report, Intel said it saw Q2 revenue of $13B, plus or minus $500M, compared to consensus at that time of $12.96B. Intel said then that it had expected its fiscal year 2014 revenue to be approximately flat, compared to consensus at that time of $53.15B. Subsequently, on June 12, Intel raised its Q2 revenue forecast to be $13.7B, plus or minus $300M, citing stronger than expected demand for business PCs. Intel added that it now expects some revenue growth for the year and that its full-year gross margin percentage is now expected to be in the upper half of the previous range of 61%, plus or minus a few percentage points, driven mostly by expected improvements in unit cost and volume. LAST QUARTER: Intel reported Q1 EPS of 38c, compared to consensus expectations at that time of 37c. The company's revenue of $12.8B was generally in-line with the consensus forecast. For the quarter, the company's gross margin came in at 59.7%. STREET RESEARCH: On the day after Intel made its positive pre-announcement, its stock was upgraded by several research firms. At that time, Morgan Stanley upgraded the shares to Equal Weight from Underweight, Roth Capital raised its rating to Buy from Neutral, and Drexel Hamilton upped its rating to Buy from Hold. Several firms also increased their price targets on Intel, with Jefferies raising its price target for Intel to $40 from $35 and Pacific Crest taking its target up to $35 from $32. Last night, coverage of Intel was initiated at Imperial Capital, which placed an Outperform rating and $37 target on the stock. NEWS: After eight quarters of declining shipments, worldwide PC shipments experienced flat growth in the second quarter of 2014, Gartner reported recently. Worldwide PC shipments totaled 75.8M units in the quarter, a 0.1% increase from the same quarter of 2013, according to Gartner. Another research firm, International Data Corporation, estimated that worldwide PC shipments totaled 74.4M units in the second quarter, marking a year-on-year decline of 1.7%. In company specific news, a July 9 report from MacRumors, citing Chinese site VR Zone, claimed that Intel has decided to further postpone the shipping of its line of 14-nanometer Broadwell chips, which are anticipated to be included in future versions of the Apple's (AAPL) MacBook Air, Retina MacBook Pro, and iMac. A report two days later from DigiTimes said that Intel is set to unveil its 14nm processors and 10nm wafers at its Developer Forum in San Francisco, citing sources from the upstream supply chain. According to the report, Intel will release the 14nm Core M-series processors in Q4 and 14nm Broadwell-based processors in January 2015. In June, The Wall Street Journal reported that Intel announced plans to package its standard server processors alongside a different class of programmable chip in a combination that includes an FPGA, or field programmable gate array. The Journal noted that FPGAs have been sold for years by Xilinx (XLNX) and Altera (ALTR), but that the general manager of Intelís data center group, Diane Bryant, declined to disclose Intelís partner on the latest effort or when the resulting products would hit the market. PRICE ACTION: Since the day after its earnings pre-announcement, Intel shares have risen over 12% and its stock is up more than 17% over the last three months. In afternoon trading ahead of tonight's report, Intel was trading near flat at $31.53.
12:48 EDTFBFacebook July weekly volatility increases into Q2
Subscribe for More Information
11:41 EDTAAPLApple CEO has 'never met' Carney, The Loop reports
Subscribe for More Information
11:07 EDTFBStocks with call strike movement; MU FB
Micron (MU) October 37 call option implied volatility increased 2% to 39, Facebook (FB) December 75 call option implied volatility increased 3% to 38 according to IVolatility.
10:56 EDTFBFed calls small cap social media, biotech valuations 'stretched'
The Board of Governors of the Federal Reserve in its Monetary Policy Report dated today said valuation metrics in "some sectors" appear substantially stretched, "particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year." A later part in the document reads, "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The specific targeting of sectors by the Fed seems to be having an impact on stocks in the social media and biotech spaces. Shares of Yelp (YELP) are down over 5% to $67.51, while Twitter (TWTR) and Facebook (FB) are each down 2%. Celgene (CELG) and Amgen (AMGN) are leading the biotech space lower with pullbacks of greater than 1%.
10:46 EDTAAPLApple rumored to solve alleged battery problem in new iPhones, AppleInsider says
According to reports from Asia, Apple is rumored to have solved its issue with the construction of ultra-thin batteries for its next-generation iPhones, says AppleInsider. Apple is said to have enlisted a new manufacturing partner in Taiwan to craft the batteries, added AppleInsider. Reference Link
10:33 EDTFBFacebook, Twitter slip following cautious valuation comments from Fed
Shares of a number of companies in the social media and biotech industries moved lower following the circulation of cautious comments about their stock valuations that were included in the Federal Reserve's latest Monetary Policy Report. WHAT'S NEW: In the report, presented by the Board of Governors of the Federal Reserve and signed on behalf of the governors by Chair Janet Yellen, the central bank wrote that some broad equity price indexes have increased to all-time highs in nominal terms since the end of 2013, but that valuation measures for the overall market in early July were "generally at levels not far above their historical averages." However, the Fed's report also cautioned that valuation metrics in some sectors do appear substantially "stretched," particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year. As support for its assessment, the Fed noted that ratios of prices to forward earnings for "smaller firms as well as social media and biotechnology firms" remain "high relative to historical norms." PRICE ACTION: Following the circulation of the comments in the Fed report, shares of Facebook (FB) are down 88c, or 1.3%, to $67.02, Twitter (TWTR) is down 24c, or 0.6%, to $38.07 and LinkedIn (LNKD), is down 21c, or 0.1%, to $159.57. Shares of some biotechnology companies including Celgene (CELG) and Amgen (AMGN) also ticked lower following the circulation of the comments from the Fed's report.
10:18 EDTFBFacebook, Twitter move lower following comments from Yellen
Subscribe for More Information
10:00 EDTGOOGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:40 EDTAAPLApple 'iWatch' said to debut in two sizes, three models, AppleInsider says
Subscribe for More Information
09:38 EDTAAPL, FBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FB JPM TSLA
07:23 EDTFBFortune to hold a conference
Subscribe for More Information
07:15 EDTGOOGIIR Holdings to hold a conference
14th Annual Shopper Insights in Action Conference to be held in Chicago on July 14-16.
06:43 EDTAAPLApple reportedly considering Carney for PR head position, Re/code reports
Subscribe for More Information
06:20 EDTAAPLBoy's rash linked to possible exposure to nickel found in iPad, WSJ reports
Subscribe for More Information
06:15 EDTGOOGGoogle Fit may benefit remote medical care industry, DigiTimes Research says
Subscribe for More Information
06:13 EDTFBFacebook, Nielsen team up to track TV habits, LA Times reports
Subscribe for More Information
06:02 EDTGOOGSamsung, Nest, ARM team up for Thread wireless networking protocol
Subscribe for More Information
05:44 EDTGOOGNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use